Navigation Links
Atritech Completes $30 Million Financing
Date:3/26/2009

Company scheduled to announce PROTECT AF results on March 28th at ACC.

MINNEAPOLIS, March 26 /PRNewswire/ -- Atritech, Inc. a clinical stage medical device company, announced today that it has completed a $30 million round of financing. Thomas, McNerney & Partners led the round along with a substantial investment from Split Rock Partners and insider investments from Prism Ventures, Tullis-Dickerson and Vector Group. Over the past 3 years, the Company has raised approximately $75 million in capital.

With this new funding, the Company will complete the Food and Drug Administration (FDA) review of the PROTECT AF clinical trial results along with the commercial launch of the WATCHMAN(R) LAA Closure Technology in Europe. The PROTECT AF clinical trial evaluates the WATCHMAN device versus the current standard of care, warfarin, in patients with atrial fibrillation. In August of 2008, Atritech announced the filing of its Pre-Market Approval Application (PMA) to the FDA. The Company will present the PROTECT AF results to the FDA's Circulatory System Devices Panel on April 23, 2009. The WATCHMAN device continues to be implanted in a Continued Access Registry (CAP) while the product is under review at the FDA. To date over 110 devices have been implanted in CAP at approximately 20 sites in the U.S. and Europe.

Atritech's WATCHMAN device is designed to keep harmful sized blood clots from entering a patient's blood stream, potentially causing a stroke. Patients with AF (a heart condition which causes the upper chambers of the heart to beat too rapidly) are at a greater risk of having a stroke. Typically these patients require blood thinning medications to prevent these clots from forming in the heart. Current medical therapy requires frequent monitoring and has diet and other drug interactions causing many patients to stop taking them. The WATCHMAN device may be an effective alternative for patients w
'/>"/>

SOURCE Atritech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Roche Completes Tender Offer for Genentech
2. Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
3. China Biologic Products Completes Acquisition of 35% Interest in Xian Huitian Blood Products Co., Ltd.
4. Sangart, Inc. Completes Series F Funding Round
5. Cardium Completes $3.5 Million Credit Facility
6. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
7. Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia
8. CIRM Completes Briefing Visit to Stemedica Cell Technologies
9. INVO Bioscience Completes Reverse Merger
10. Particle Sciences Completes Development of First Product Incorporating its Unique Surface Modification System
11. Mach One Corporation Completes Acquisition of Ceres Organic Harvest, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... PHILADELPHIA , July 1, 2015 ... technology will ... s evidence-based clinical s olutions suite ... scientific, technical and medical information products and services, announced today ... -based clinical decision support (CDS) technology company. InferMed,s ...
(Date:7/1/2015)... 2015  UCB, a multinational biopharmaceutical company, and ... in designing, transforming, and running intelligent business operations, ... of their close collaboration in driving transformation that ... services (GBS) finance organization. The Aecus ... work together effectively to embrace the innovative promise ...
(Date:6/30/2015)... 2015 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced ... Resverlogix have approved the resolutions relating to: (i) ... 5,600,000 units at a price of $2.67 per ... comprised of one common share and 0.075358 common ... CAD$15 million; and (ii) the amendment to Resverlogix,s ...
(Date:6/30/2015)... , June 30, 2015  Juniper Pharmaceuticals, Inc. (Nasdaq: ... on developing therapeutics that address unmet medical needs ... George Elston will present at the Cantor ... July 8, 2015Time: , 4:45 PM EDTLocation: , ... & archive): , www.juniperpharma.com, under  ,Investor, ...
Breaking Biology Technology:Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2
... Agreement Signed in Third Quarter of 2008 Expands ... Application of Cutting-Edge Influenza Vaccine Technology, GAITHERSBURG, ... has licensed its proprietary reverse genetics intellectual property,to ... support,the development and construction of new vaccine strains ...
... Ariz., Oct. 16 A team of researchers ... quantitative mass,spectrometry immunoassay for the detection of bioactive ... on Oct. 14 in the journal of,Circulation: Heart ... Fremont, Christ Hospital in Cincinnati, and Medivation Inc. ...
... MDVN ) today announced that it will ... Society of America (HDSA), which honors,those companies that ... other neurodegenerative diseases. David Hung, M.D., president,and chief ... during the,12th Annual Guthrie Awards Dinner on Thursday, ...
Cached Biology Technology:MedImmune Licenses Reverse Genetics Technology to Hungary's Omninvest for Use in Influenza Vaccine Development and Production 2Novel Mass Spectrometry-based Assay Reveals Degradation and Low Levels of Bioactive B-type Natriuretic Peptide (BNP) in Patients with Heart Failure 2Medivation Receives Corporate Achievement Award From Huntington's Disease Society of America 2Medivation Receives Corporate Achievement Award From Huntington's Disease Society of America 3
(Date:6/24/2015)... 2015 Research and ... the "Huawei Ascend Mate 7 Fingerprint Sensor ... offering. Huawei,s technological choice for the ... than Apple,s and Samsung,s one. The Ascend Mate ... Fingerprint Cards, a main actor in capacitive sensing ...
(Date:6/23/2015)... RALEIGH, N.C. , June 23, 2015 /PRNewswire/ ... technology, today announced the results of a recent ... unmatched accuracy on the wrist during activity. In ... biometric technology was compared along with the Apple ... for accurately measuring heart rate during activity. The ...
(Date:6/17/2015)... , Deutschland und GERMANTOWN, Maryland ... Investigator ®   Produktlinie mit DNA-Tests ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... neue STR-Testkits der Produktlinie Investigator ... in den Markt eingeführt. Die neuen Kits zur Erstellung ...
Breaking Biology News(10 mins):Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6
... found black smoker vents farther north than anyone has ever ... nearly four stories in height are venting water as ... vent water hits the icy cold of the deep sea ... what is one of the most massive hydrothermal sulfide deposits ...
... Researchers at The Pennsylvania State University College of Medicine, ... a clinically important immune response modifier with potent antiviral ... Factor (OGF)-OGF receptor (OGFr) axis for its action. ... Experimental Biology and Medicine , provides new insights ...
... might tell potential suitors, "I like the way you ... worms send their valentines via signals known as pheromones, ... to a study published Wednesday (July 23) in the ... University of Florida, Cornell University, the California Institute of ...
Cached Biology News:Scientists break record by finding northernmost hydrothermal vent field 2Scientists break record by finding northernmost hydrothermal vent field 3Imiquimod, an immune response modifier, is dependent on the OGF-OGFr signaling pathway 2Mate or hibernate? That's the question worm pheromones answer 2Mate or hibernate? That's the question worm pheromones answer 3
... The versatile ST-195 allows real-time observations of ... This instrument has 64 different strain parameters ... incubator. The thin silicon strain chamber used ... microscopes and fluorescence microscopy. ST-195 can be ...
... Control and regulate cell stretching or compression ... microscope stage. Computer controlled so you can ... the strain to produce 64 unique strain ... then the ST-150. Both models are compatible ...
... reagents package is used for determining protein concentration ... The RC DC protein assay is a colorimetric ... standard assays: 250 ml RC reagent I, 250 ... tartrate solution, 2 L dilute Folin reagent, and ...
... Kit is used in conjunction with the EasyCount ... automatically. The ViaSure Staining Reagent uses a ... Orange and Ethidium Bromide to identify live and ... the EasyCount Slide 6 Multi-well Slide provides ...
Biology Products: